ARS Pharmaceuticals (SPRY) Interest Coverage Ratio (2020 - 2026)
ARS Pharmaceuticals (SPRY) reported Interest Coverage Ratio of 1.69 for Q1 2026, up 99.95% on a YoY basis from 0.85 in Q1 2025, and up 90.49% sequentially from 17.78 in Q4 2025.
ARS Pharmaceuticals (SPRY) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 7 years of Interest Coverage Ratio data on file, last reported at 1.69 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 99.95% year-over-year to 1.69; the trailing twelve-month figure through Mar 2026 stood at 5.69 (up 99.77% YoY), and the FY2025 full-year result was 2.3, down 5224.51% from the prior year.
- Interest Coverage Ratio climbed to 1.69 in Q1 2026, from 17.78 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.0 in Q1 2023 to a low of 3379.73 in Q1 2025.
- A 5-year average of 238.45 and a median of 0.83 in 2022 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio soared 99.97% in 2023 and slumped 1986412.08% in 2025, its largest moves.
- Tracing SPRY's Interest Coverage Ratio over 5 years: stood at 154.43 in 2022, then jumped by 100.0% to 0.0 in 2023, then tumbled by 22032750.92% to 256.51 in 2024, then jumped by 93.07% to 17.78 in 2025, then soared by 90.49% to 1.69 in 2026.
- Business Quant data shows SPRY's Interest Coverage Ratio at 1.69 in Q1 2026, 17.78 in Q4 2025, and 0.89 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -0.38 |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -1.69 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.69 |
| Dec 31, 2025 | -17.78 |
| Sep 30, 2025 | -0.89 |
| Jun 30, 2025 | -0.27 |
| Mar 31, 2025 | -3,379.73 |
| Dec 31, 2024 | -256.51 |
| Sep 30, 2024 | -0.16 |
| Jun 30, 2024 | -0.29 |
| Mar 31, 2024 | -0.17 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | -154.43 |
| Sep 30, 2022 | -0.78 |
| Jun 30, 2022 | -0.88 |
| Mar 31, 2022 | -1.58 |
| Dec 31, 2021 | -87.47 |
| Sep 30, 2021 | -1.04 |
| Jun 30, 2021 | -0.20 |
| Mar 31, 2021 | -44.86 |